BIBN 99

From Food & Medicine Encyclopedia

Revision as of 03:34, 2 December 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

BIBN 99 is a synthetic compound that has been studied for its potential use in the treatment of various neurological disorders. It is primarily known for its role as a selective antagonist of the neurokinin 1 receptor (NK1 receptor), which is involved in the modulation of pain and inflammation.

Chemical Structure and Properties[edit]

BIBN 99 is a small molecule with a complex chemical structure designed to specifically bind to the NK1 receptor. The molecular formula of BIBN 99 is C_33H_35N_5O_4, and it has a molecular weight of 569.67 g/mol. The compound is characterized by its high affinity for the NK1 receptor, which is a member of the tachykinin receptor family.

Mechanism of Action[edit]

BIBN 99 functions as an antagonist at the NK1 receptor, which is a G-protein coupled receptor (GPCR) that binds the neuropeptide substance P. By blocking the action of substance P, BIBN 99 can inhibit the transmission of pain signals in the central nervous system. This makes it a potential candidate for the development of new analgesic drugs.

Pharmacological Effects[edit]

Studies have shown that BIBN 99 can effectively reduce pain and inflammation in animal models. It has been investigated for its potential use in treating conditions such as migraine, chronic pain, and inflammatory diseases. The compound's ability to selectively target the NK1 receptor without affecting other receptors is a significant advantage, as it reduces the likelihood of side effects.

Clinical Applications[edit]

While BIBN 99 has shown promise in preclinical studies, its clinical development has been limited. Further research is needed to fully understand its pharmacokinetics, safety profile, and therapeutic efficacy in humans. However, its mechanism of action suggests that it could be beneficial in treating a variety of conditions associated with pain and inflammation.

Research and Development[edit]

Ongoing research is focused on optimizing the pharmacological properties of BIBN 99 and exploring its potential in combination therapies. Scientists are also investigating its effects on other neurological pathways and its potential role in neurodegenerative diseases.

Also see[edit]


Pharmacomodulation
Types
Classes
Enzyme
Ion channel
Receptor &
transporter
Miscellaneous


Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=BIBN_99&oldid=6023096"